The Medical Letter on Drugs and Therapeutics
Another Insulin Glargine (Basaglar) for Diabetes
The full article is available to subscribers Subscriber Login   
Revised 1/20/17: In the Dosage and Administration paragraph, we removed the word "syringe" in describing Basaglar's KwikPen device. Basaglar is not available as a prefilled syringe; it is only available as a KwikPen.

The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin glargine (Toujeo) was approved in 2015.1

INSULIN GLARGINE — A recombinant DNA analog of human insulin, insulin glargine forms microprecipitates in subcutaneous tissue, prolonging its duration of action to a mean of about 24 hours.2 It has less peak-to-trough variation and causes less nocturnal hypoglycemia than NPH insulin.

CLINICAL STUDIES — Approval of Basaglar was based on data demonstrating the clinical efficacy and safety of Lantus.3 Comparative studies have found no significant differences in the pharmacokinetics, toxicity, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Another Insulin Glargine (Basaglar) for Diabetes
Article code: 1511b
 Electronic, downloadable article - $25